Skip to main content
. Author manuscript; available in PMC: 2008 Oct 1.
Published in final edited form as: Lung Cancer. 2007 Jul 3;58(1):95–103. doi: 10.1016/j.lungcan.2007.05.017

Table 6.

Gefitinib-related adverse events

Skin Diarrhea ILD
Source (reference) Grades 1-2/no. pts (%) Grades 3-4/no. pts (%) Grades 1-2/no. pts (%) Grades 3-4/no. pts (%) Grades 1-4/no. pts (%)
Inoue (43) 12/16 (75%) 0/16 (0%) 3/16 (19%) 0/16 (0%) 0/16 (0%)
Asahina (44) 7/16 (44%) 1/16 (6%) 7/16 (44%) 0/16 (6%) 1/16 (6%)
Sutani (45) 9/27 (78%) 1/27 (18.5%) 5/27 (3.5%) 0/27 0/27 (0%)
Yoshida (46) 6/21 (28.5%) 0/21 (0%) 6/21 (28.5%) 2/21 (9.5%) 0/21 (0%)
Sunaga (47) 13/21 (62%) 1/21 (4.7%) 2/21 (9.5%) 0/21 (0%) 1/21 (4.7%)
Total 47/101 (46.5%) 3/101 (3%) 23/101 (23%) 2/101 (2%) 2/101 (2%)

no. pts, number of patients; ILD, interstitial lung disease